medigraphic.com
ISSN 2078-7170 (Electronic)

2016, Number 4

<< Back Next >>

CorSalud 2016; 8 (4)

Dual antiplatelet therapy in patients with ST-segment elevation acute myocardial infarction and thrombolytic treatment

Castro HFM, Alonso MAL, Ramírez GJI, Alonso MOL

Language: Spanish
References: 22
Page: 217-226
PDF size: 846.07 Kb.


ABSTRACT

Introduction: Acute coronary syndromes are usually due to plaque rupture, platelet activation, and thrombus formation leading to coronary occlusion and myocardial injury. The use of acetylsalicylic acid, clopidogrel and low molecular weight heparin have reduced the risk of death, myocardial infarction and ischemia recurrence.
Objective: To describe the clinical course and benefits of dual antiplatelet therapy associated with thrombolytic therapy in patients with ST-segment elevation acute myocardial infarction (STEMI).
Method: A descriptive, cross-sectional, non-randomized, multicenter study was performed between October 2012 and December 2014 at the Intensive Care Units from "Arnaldo Milián Castro", "Celestino Hernández Robau" and "Placetas" University Hospitals in Villa Clara, Cuba. The study population consisted of 86 patients divided into study and control groups, who met the inclusion criteria.
Results: STEMI was more frequent in males and between 70-75 years. Most frequent risk factors were smoking and hypertension in 57.0% of patients in both groups. The anterior wall location presented more complications; patients with inferior location of the infarction were the most benefited with dual antiplatelet therapy. It was found in the study group that the earlier the treatment, the better the evolution and the lower the in-hospital mortality.
Conclusions: Dual antiplatelet therapy in patients with STEMI, receiving thrombolytic therapy, decreased ischemic complications frequency.


REFERENCES

  1. Erdem G, Flather M. Evaluación del riesgo de hemorragia en los síndromes coronarios agudos. Rev Esp Cardiol. 2012;65:4-6.

  2. Kaul U, Sethi KK, Dalal J, Parikh K, Hiremath MS, Mullasari AS, et al. A multicentre retrospective study to understand anti-platelet treatment patterns and outcomes of acute coronary syndrome patients in India (TRACE). Indian Heart J. 2014;66: 334-9.

  3. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST segment elevation. N Engl J Med. 2005;352:1179-89.

  4. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Rev Esp Cardiol. 2012;65:173.e1-55.

  5. Fisch AS, Perry CG, Stephens SH, Horenstein RB, Shuldiner AR. Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep. 2013;15:381.

  6. Steg G, James SK, Atar D, Badano LP, Blomstrom Lundqvist C, Borger MA, et al. Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. Rev Esp Cardiol. 2013;66:53.

  7. Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, et al. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2014;35:1541-50.

  8. Pinar E, Bardají A. Manejo del infarto agudo de miocardio con elevación del segmento ST. Guías de actuación clínica y el mundo real. Rev Esp Cardiol Supl. 2009;09:C71-8.

  9. Correia LC, García G, Kalil F, Ferreira F, Carvalhal M, Oliveira R, et al. Prognostic value of TIMI score versus GRACE score in ST-segment elevation myocardial infarction. Arq Bras Cardiol. 2014; 103:98-106.

  10. Cho YK, Nam CW, Park HS, Yoon HJ, Kim H, Hur SH, et al. Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation. Korean J Intern Med. 2014;29:210-6.

  11. Rakowski T, Dziewierz A, Siudak Z, Kleczyński P, Dubiel JS, Dudek D. Introduction of new oral antiplatelet drugs in myocardial infarction hospital network: initial experience. J Thromb Thrombolysis. 2014;37:243-5.

  12. Wang X, Yu H, Li Z, Li L, Zhang Y, Gao W. Association between peak neutrophil count, clopidogrel loading dose, and left ventricular systolic function in patients with primary percutaneous coronary intervention. Mediators Inflamm [Internet]. 2014 [citado 18 Abr 2016];2014:482763. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131512/pdf/MI2014-482763.pdf

  13. López LR, Guyer KE, Torre IG, Pitts KR, Matsuura E, Ames PR. Platelet thromboxane (11-dehydroThromboxane B2) and aspirin response in patients with diabetes and coronary artery disease. World J Diabetes. 2014;5:115-27.

  14. Deshpande A, Birnbaum Y. ST-segment elevation: distinguishing ST elevation myocardial infarction from ST elevation secondary to nonischemic etiologies. World J Cardiol. 2014;610:1067-79.

  15. Redfern J, Hyun K, Chew DP, Astley C, Chow C, Aliprandi-Costa B, et al. Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand. Heart. 2014; 100:1281-8.

  16. Hong KS. Dual antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack: pros and cons. J Clin Neurol. 2014;10:189- 96.

  17. Chua D, Nishi C. New antiplatelet agents for cardiovascular disease. CMAJ. 2013;185:1405-11.

  18. Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, et al. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?. Am Heart J. 2014;168:611-21.

  19. Schroeder JS, Frishman WH, Parker JD, Angiolillo DJ, Woods C, Scirica B. Pharmacologic options for treatment of ischemic disease. In: Antman EM, Sabatine M, editors. Cardiovascular therapeutics – A Companion to Braunwald’s Heart Disease. 9th ed. Philadelphia: Saunders; 2013. p. 95-142.

  20. Patel V, Lin FJ, Ojo O, Rao S, Yu S, Zhan L, et al. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada). 2014;12;438.

  21. Olivier C, Diehl P, Bode C, Moser M. Thrombin receptor antagonism in antiplatelet therapy. Cardiol Ther. 2013;2:57-68.

  22. Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014;34:1077-90.




2020     |     www.medigraphic.com